Congenital cytomegalovirus infection treatment

On 6 November 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number number 408. The active ingredient is human cytomegalovirus immunoglobulin for prevention of congenital cytomegalovirus infection following primary cytomegalovirus infection.